The discovery of the JAK2V617F mutation in most patients with Ph-negative myeloproliferative neoplasms (MPNs) has led to the development of JAK2 kinase inhibitors. However, JAK2 inhibitor therapy has shown limited efficacy and doselimiting hematopoietic toxicities in clinical trials. In this report, we describe the effects of vorinostat, a small molecule inhibitor of histone deacetylase, against cells expressing 
Introduction
Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic malignancies that include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) 1, 2 . These diseases are characterized by excessive proliferation of myeloid/erythroid lineage cells. A somatic point mutation (V617F) in the JAK2 tyrosine kinase has been found in most patients with PV and 50-60% patients with ET and PMF [3] [4] [5] [6] . JAK2V617F is a constitutively active tyrosine kinase that can transform factor-dependent hematopoietic cell lines to cytokine independence 3, 4 . Expression of JAK2V617F mutant activates multiple downstream signaling pathways, such as signal transducer and activator of transcription (Stat), extracellular signal-regulated kinase (Erk), and phosphatidylinositol 3-kinase/Akt pathways 3, 7, 8 .
Current therapies for MPNs include phlebotomy and myelosuppressive therapy (e.g., hydroxyurea, anagrelide) for PV and ET, transfusions and supportive care for PMF.
These empiric treatments are unlikely to cure or offer remission to patients with MPNs.
Thus, there is a clear need for new therapies for MPNs. The discovery of the JAK2V617F mutation in PV, ET and PMF has led to the development of inhibitors of JAK2. Several JAK2 inhibitors are undergoing clinical trials. Although JAK2 inhibitors are effective in reducing splenomegaly and improving constitutional symptoms, significant hematopoietic toxicities including anemia and thrombocytopenia are observed in a majority of patients treated with the JAK2 inhibitors 9, 10 , consistent with the known function of JAK2 in normal hematopoiesis 11, 12 . Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for treatment of myelofibrosis. However, a recent report on long-term
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From outcomes with Ruxolitinib treatment shows improvement in constitutional symptoms but no significant benefit in survival of myelofibrosis patients 13 . In addition, there is an increased rate of discontinuation of Ruxolitinib therapy due to severe hematopoietic toxicities or lack of response 13 . It is also possible that drug resistance may emerge in some patients treated with JAK2 inhibitors similar to that observed with ABL inhibitor imatinib in CML patients 14 . Therefore, identifying additional new therapies targeting JAK2V617F or pathways downstream of JAK2V617F would be beneficial for treatment of patients with MPNs.
Acetylation is an important post-translational modification that serves as a key modulator of chromatin structure and gene transcription, and provides a mechanism for coupling extracellular signals with gene expression 15 . This process is regulated by two classes of enzymes-the histone acetyltransferases (HATs) and the histone deacetylases (HDACs) that catalyze the acetylation or deacetylation of histones. Inhibition of HDAC activity has been linked to hematopoietic stem cell (HSC) proliferation and self-renewal [16] [17] [18] [19] [20] . Aberrant acetylations of histones and other cellular proteins have been found in leukemia, lymphoma and solid tumors 15, 21 . Pharmacological inhibition of HDACs has shown promise in treating hematologic malignancies and other forms of cancer 15, 21 .
Several HDAC inhibitors including trichostatin A (TSA), valproic acid, depsipeptide, vorinostat, ITF2357 (givinostat) and panobinostat have been shown to cause death of cancer cells in vitro and in vivo 15, [21] [22] [23] [24] . Vorinostat (also known as SAHA or Zolinza®), a small molecule inhibitor of class I and II HDACs, has been shown to induce growth arrest and promote apoptosis of a variety of cancer cells 15, 21, 25, 26 . It is an FDA approved drug for treatment of refractory cutaneous T-cell lymphoma (CTCL) 27 .
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Vorinostat has also demonstrated activity against leukemias and solid tumors in preclinical and Phase I clinical studies 15, 21, 28, 29 . Increased HDAC activity has been found in patients with PMF 30 . In vitro treatment of PMF CD34+ cells with 5-azacytidine plus TSA or vorinostat resulted in a significant decrease in the proportion of JAK2V617F
homozygous colonies and marked reduction of JAK2V617F-positive SCID repopulating cells 23, 31 . Moreover, a beneficial effect of HDAC inhibition was observed in a patient with JAK2V617F-positive advanced myelofibrosis 32 . Other HDAC inhibitors including ITF2357 (givinostat) and panobinostat also showed potent anti-proliferative and proapoptotic activity against murine and human cells expressing JAK2V617F 24, 33 . Thus, inhibition of HDAC could be useful in treating MPNs. In the present studies, we have tested the efficacy of vorinostat in an animal model of Jak2V617F-positive MPN 7 . We have reported earlier that expression of Jak2V617F in knock-in mice reproducibly produced all the features of human PV 7 . We have utilized this Jak2V617F knock-in mouse model to test the in vivo effects of vorinostat. Our results show that vorinostat treatment significantly improves peripheral blood counts and attenuates splenomegaly in knock-in mice expressing Jak2V617F. 
Methods

Reagents and antibodies
Cell cultures
HEL, K562 and murine BA/F3-EpoR-JAK2V617F cells were maintained in RPMI-1640 medium with 10% FBS plus penicillin/streptomycin. UKE cells were maintained in RPMI-1640 medium plus penicillin/streptomycin supplemented with 10% FBS, 10% donor horse serum and 1 μM hydrocortisone. Primary erythroblasts were generated from the bone marrow of MxCre;Jak2V617F/+ mice as previously described 34 .
Cell proliferation and viability assays
Viable cells were plated at 3,000 cells (for BA/F3-EpoR-JAK2V617F cells) or 10,000 cells (HEL, UKE and K562 cells) per well in 96-well plates. Cells were treated with DMSO or vorinostat (0.0625 μM to 1.0 μM) for 48 hours. Cell proliferation was measured by WST assay using a Quick Cell Proliferation Assay Kit (Biovision, CA).
For cell viability measurement, 5 x 10 5 cells were cultured in RPMI-1640 medium with 10% FBS in the presence of DMSO or vorinostat (0.5 μM, or 1.0 μM). Viable cell number was assessed by trypan blue exclusion every 24 hours for 5 days.
Apoptosis and cell cycle analysis
The proportion of apoptotic cells was determined by Annexin V staining. The cells were treated with DMSO or vorinostat for 24 hours. Cells were harvested and stained with
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For cell cycle analysis, cells were treated with DMSO or 1.0 μM vorinostat for 24 hours. Cells were fixed in 100% ethanol and stained with PI. Cells were recorded using a BD LSRII flow cytometer and the cell cycle distribution was analyzed by Modfit software.
Colony-forming Assay
BA/F3-EpoR-JAK2V617F, HEL, and K562 cells were plated (250 cells/dish) in duplicates in methylcellulose medium (M3234, Stem Cell Technologies) without any cytokine in the presence of DMSO or vorinostat (0.5 μM or 1.0 μM). Colonies were counted on day 5. To detect erythropoietin (Epo)-independent colony-forming unit erythroid (CFU-E) colonies, spleen cells from MxCre;Jak2V617F/+ mice were plated (1 X 10 5 cells/dish) in duplicate in methylcellulose medium (M3234, Stem Cell Technologies) without any cytokine in the presence of DMSO or vorinostat (0.5 μM or 1.0 μM). CFU-E colonies were counted after 2 days following staining with benzidine solution (Sigma).
Flow cytometry
BM and spleen cells from placebo and vorinostat-treated mice were stained with APCconjugated Ter119 and PE-conjugated CD71 monoclonal antibodies (eBioscience, San Diego, CA) for 20 min on ice. Flow cytometry was performed with an LSRII (Beckton-
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Deckinson, San Diego, CA) and analyzed by using FlowJo software (TreeStar, Ashland, OR).
Immunoblotting and immunoprecipitation
For immunoblot analysis, cells were harvested after treatment with vorinostat (0.5 μM or 1.0 μM) for 24 hours. Cells were lysed and equal amounts of proteins were separated by SDS-PAGE. Immunoblotting was performed using phospho-specific or total antibodies as indicated. For loading controls, blots were reprobed with anti-total Erk2 antibodies. 
Real-time quantitative PCR
Total RNA was extracted from the HEL cells after treatment with vorinostat (0.5 μM or 1.0 μM) using the RNeasy Mini Kit (Qiagen, CA). Reverse transcription was carried out with 200 ng of total RNA using QuantiTect reverse transcription kit (Qiagen, CA).
Quantitative real-time PCR for JAK2, SOCS1, SOCS3, GATA1, KLF1, FOG1, SCL, C/EBPα, PU.1 and NF-E2 was performed using the SYBR Green PCR Master mix (Applied Biosystems). The primers used for real-time PCR are listed in the Supplemental 
Animal studies with vorinostat
A conditional Jak2V617F knock-in mouse was generated as described previously 7 .
Expression of Jak2V617F was induced in MxCre;Jak2V617F/+ mice by injection with polyinosine:polycytosine (pI:pC) 7 . Peripheral blood counts were measured four weeks after pI:pC induction to confirm the establishment of PV disease in these mice. 
Blood and tissue analysis
Peripheral blood counts were measured using Hemavet 950FS (Drew Scientific). Blood smears were stained with Wright-Giemsa. For histopathologic analysis, mouse tissue specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Tissue sections (4 μm) were stained with hematoxylin and eosin (H&E).
Statistical analysis
Results are expressed as mean ± SEM, and data were analyzed by the two-tailed Student's t-test. P <0.05 was considered to be statistically significant.
Results
Vorinostat significantly inhibits proliferation of cell lines expressing JAK2V617F
We first determined the effects of vorinostat on proliferation of hematopoietic cell lines 
Vorinostat inhibits primary erythroblasts expressing JAK2V617F
Expression of JAK2V617F in hematopoietic stem cells/progenitors results in skewing towards erythroid lineage and expansion of erythroid progenitors 7, 36 . So, we asked whether vorinostat could inhibit the growth of primary erythroblasts expressing JAK2V617F. Primary erythroblasts were derived from the bone marrow of Jak2V617F knock-in mice as previously described 34 . Jak2V617F-expressing primary erythroblasts were plated in a 96 well plate in the presence of vehicle (DMSO) or vorinostat at various concentrations (0.0625-1.0 μM) for 48 hours, and proliferation was measured by WST assay. Proliferation of murine erythroblasts expressing Jak2V617F was significantly inhibited by vorinostat in a dose-dependent manner ( Figure 3A ).
Expression of JAK2V617F results in Epo-independent erythroid colonies in the BM and spleens of mice and humans 7, 37 , a hallmark feature of PV. So, we tested the effects of vorinostat on JAK2V617F-evoked Epo-independent CFU-E colony formation in the spleens of mice expressing Jak2V617F. As shown in Figure 3B , vorinostat treatment at 0.25 μM reduced Epo-independent CFU-E colonies by ~70%. At higher doses of vorinostat (0.5-1.0 μM), Epo-independent CFU-E colonies were almost completely inhibited in the spleens of mice expressing Jak2V617F (MxCre;Jak2V617F/+) ( Figure 3B ). Thus, vorinostat markedly inhibited Epoindependent erythroid colony formation mediated by JAK2V617F. We also compared the effects of vorinostat with JAK inhibitor on Epo-independent erythroid colony formation
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From mediated by JAK2V617F. Whereas vorinostat at 1 μM completely inhibited Epoindependent CFU-E colony formation, treatment with JAK inhibitor I at 2 μM concentration, which almost completely inhibited JAK2 kinase activity (as described in 4 and data not shown), exhibited ~50% reduction in Epo-independent CFU-E colonies in the spleens of Jak2V617F mice ( Figure 3C ). These results suggest that vorinostat could be more potent than JAK inhibitor in inhibiting Epo-independent erythroid colony formation mediated by JAK2V617F.
Next, we asked if vorinostat has any toxic effect towards normal wild type hematopoietic progenitors. To address this question, we compared bone marrow progenitors from wild type mice treated with vorinostat (0.5-1.0 μM) to those with vehicle treatment by performing hematopoietic progenitor colony-forming assays in the presence of cytokine. Treatment with vorinostat (0.5-1.0 μM) exhibited little effect on erythroid (CFU-E, BFU-E) and myeloid (CFU-GM) colony formation in the bone marrow of wild type mice ( Figure 3D ). Together, these results suggest that vorinostat preferentially inhibit the clonogenic growth of primary erythroid progenitors expressing Jak2V617F without exhibiting significant toxicity towards wild-type Jak2-expressing normal hematopoietic progenitors in mice.
Vorinostat inhibits clonogenic growth of PV hematopoietic progenitors expressing
JAK2V617F
We next examined the effects of vorinostat on the clonogenic growth of MPN primary hematopoietic progenitors. We isolated CD34 + cells from patients with JAK2V617F-positive PV and ET and from wild type JAK2-expressing healthy volunteers. Treatment with vorinostat (0.5-1.0 μM) significantly reduced hematopoietic progenitor colonies in JAK2V617F-positive PV CD34 + cells ( Figure 3E ). In contrast, no significant inhibition of hematopoietic progenitor colonies was observed in healthy control samples ( Figure   3E ). However, vorinostat treatment only modestly inhibited hematopoietic progenitor colonies in ET samples. Overall, the effect of vorinostat was significantly greater on hematopoietic progenitors from patients with PV than with ET ( Figure 3E ).
We also have evaluated the effects of vorinostat on the growth of primary MPN cells. We cultured the PV and normal control CD34 + cells in a serum-free medium with cytokines that enriches the erythroid cells 35 . We found that erythroid cells from MPN patients were significantly more (>2 fold) inhibited by vorinostat treatment than healthy control erythroid cells ( Figure 3F ). Thus, primary MPN cells are more sensitive to vorinostat than normal cells.
Vorinostat downregulates expression of JAK2V617F and affects its downstream targets
To gain insight into the mechanism of inhibition of cells expressing JAK2V617F by We also assessed the effects of vorinostat on the expression of suppressor of cytokine signaling (SOCS) molecules, which are known to negatively regulate the JAK- 
Vorinostat induces significant hematologic response in a murine model of polycythemia vera
Since vorinostat significantly inhibited cells expressing JAK2V617F, we asked if vorinostat could be useful in treating PV using our Jak2V617F knock-in mouse model 7 .
To assess the effects of vorinostat on Jak2V617F-induced PV, we first established PV disease in MxCre;V617F/+ mice by injecting pI:pC. Four weeks after induction, the disease was confirmed by peripheral blood counts. Animals were then randomized to Figure 6D ). Together, these results suggest that vorinostat could be efficacious in treating PV.
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Vorinostat treatment decreases JAK2V617F mutant allele burden in a murine model
Since we observed that vorinostat treatment significantly improved blood parameters and reduced splenomegaly in Jak2V617F knock-in mice ( Figure 5A-F) , we asked whether vorinostat treatment could reduce the Jak2V617F mutant allele burden. To address this question, we generated a chimeric mouse model by mixing BM from the Jak2V617F knock-in mice (CD45.2 + ) with the BM from wild type (CD45.1 + ) mice at a ratio of 3 to 1 (75% V617F versus 25% WT) and injected it into lethally irradiated wild type CD45.1 + recipient animals, as outlined in Figure 7A . As expected, the transplanted chimeric mice exhibited high hematocrit levels and high percentage (~70%) of CD45. Together, these results provide strong evidence that vorinostat treatment can reduce the mutant allele burden in vivo.
Discussion
The JAK2V617F mutation is the most common somatic mutation found in PV, ET and 9, 10, 13 . Complete remissions similar to those seen in CML with the BCR-ABL inhibitor imatinib cannot be achieved with the JAK2 inhibitors. Thus, it is very likely that JAK2 inhibitor alone would not be sufficient to effectively treat MPNs. So, there is a clear need for development/identification of alternative therapeutic approaches for treatment of MPN patients.
In this report, we evaluate the efficacy of HDAC inhibitor vorinostat in hematopoietic cell lines and primary hematopoietic progenitors expressing JAK2V617F
and in a murine model of PV. We tested vorinostat for several reasons. Vorinostat is a FDA approved drug for treatment of refractory CTCL and is currently under investigation in several other neoplasms. We demonstrate that vorinostat treatment significantly inhibits the growth of murine and human hematopoietic cells and progenitors expressing JAK2V617F. Other HDAC inhibitors including ITF2357 (givinostat) and panobinostat also showed activity against JAK2V617F-expressing cells 24, 33 . Treatment with vorinostat in vivo resulted in significant improvement in peripheral blood counts with normalization of RBC, hemoglobin and hematocrit in the Jak2V617F knock-in mice ( Figure 5A-D) . We also observed marked improvements in bone marrow and spleen architecture, and significant reduction in splenomegaly ( Figure 5F and Figure 6 ). Moreover, vorinostat treatment reduced the mutant allele burden in mice ( Figure 7) . Thus, our data show that vorinostat may have therapeutic potential for treatment of PV.
We did not observe anemia in control animals treated with vorinostat (Supplemental Figure 1) . We have treated the control and Jak2V617F knock-in mice for short-term only. However, a toxicological study on long-term effects of vorinostat Recent studies indicate that JAK2V617F is also an HSP90 client protein 24, 45 . Indeed, we observed dissociation of JAK2V617F with HSP90 upon vorinostat treatment ( Figure 4D ). However, the mechanism by which vorinostat inhibits transcription of JAK2V617F is unclear.
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From Myc and Pim 1 are known as downstream targets of JAK2V617F and are required for JAK2V617F-mediated transformation 46 . We observed marked reduction in c-Myc and Pim-1 in vorinostat-treated HEL cells ( Figure 4B ). Also, significant cleavage of caspase 3 and PARP was observed in HEL cells treated with vorinostat ( Figure 4B) consistent with increased apoptosis in HEL cells upon vorinostat treatment.
A recent study has shown that hyperacetylation of SOCS1 and SOCS3 promoters by TSA treatment increases their expression in colorectal cancer cells 47 . We also observed significant increase in SOCS1 and SOCS3 expression in vorinostat-treated HEL cells ( Figure 4E ). Thus, vorinostat treatment not only decreases expression of JAK2V617F/Stat5/Stat3 but also increases expression of the negative regulators (SOCS1 and SOCS3) of the JAK/Stat pathway.
We also observed significant decrease in expression of several transcription factors including GATA1, KLF1, FOG1, SCL, C/EBPα, PU.1 and NF-E2 in vorinostattreated HEL cells ( Figure 4F ). GATA1, KLF1, FOG1, SCL and NF-E2 control erythropoiesis 41, 42 , whereas PU.1 and C/EBPα are important for granulopoiesis/monopoiesis 43 . Interestingly, upregulation of NF-E2 and PU.1 expression was observed in MPN 48, 49 . In addition, it has been found recently that overexpression of NF-E2 induces MPN in mice and vorinostat treatment can reduce the NF-E2 expression 50 . Thus, it is plausible that vorinostat may inhibit the growth of JAK2V617F-expressing hematopoietic progenitors by inhibiting the expression of transcription factors that control erythropoiesis and myelopoiesis. Future studies will determine how inhibition of HDAC by vorinostat regulates the expression of these transcription factors.
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We observed that the growth of JAK2V617F-expressing primary erythroid precursors from mice and humans was remarkably inhibited by vorinostat treatment (Figure 3) . Interestingly, vorinostat was more potent than JAK inhibitor I at inhibiting erythroid progenitors expressing JAK2V617F (Figure 3B,C) . We also observed that the effect of vorinostat was significantly greater on hematopoietic progenitors from PV than ET ( Figure 3E 
